<DOC>
	<DOC>NCT00600288</DOC>
	<brief_summary>The purpose of this pilot study is to evaluate the effect of diquafosol tetrasodium Ophthalmic Solution, 2% in dry eye subjects.</brief_summary>
	<brief_title>Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634)</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Provide written informed consent prior to any study procedures being performed. Have a best corrected visual acuity (BCVAof +0.7 or better. Have a history of dry eye (keratoconjunctivitis sicca) in both eyes Have ongoing dry eye disease, in the same qualifying eye or both eyes. Have previously had LASIK refractive surgery. Use of topical ophthalmic medications, preps, gels and lid scrubs during study. Have had penetrating intraocular surgery in the past 90 days. Have had other ocular surface surgery (e.g., refractive, pterygium) within the past year. Have a diagnosis of an ongoing ocular infection, clinically significant blepharitis, lid margin inflammation, StevensJohnson syndrome or pemphigoid. Any serious ocular systemic disease or uncontrolled medical condition. Exposure to any investigational drug within 30 days of study start.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>